Zydus Lifesciences Receives USFDA Approval for Generic Blood Disorder Drug

Zydus Lifesciences has received final approval from the US Food and Drug Administration for its generic Eltrombopag tablets, used to treat thrombocytopenia in specific blood disorders. The approval covers multiple strengths—12.5 mg, 25 mg, 50 mg, and 75 mg—and production will take place at the company's Ahmedabad facility. The drug, which stimulates platelet production, had annual US sales of approximately USD 1.26 billion as of November 2025, according to IQVIA data.